{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T00:02:56Z","timestamp":1791072176205,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.euo.2025.06.009","type":"journal-article","created":{"date-parts":[[2025,7,19]],"date-time":"2025-07-19T03:50:51Z","timestamp":1752897051000},"page":"294-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6617-5522","authenticated-orcid":false,"given":"Soumyajit","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilun","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Eastham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gleave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.D.","family":"Wallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himisha A.","family":"Beltran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela Y.","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas G.","family":"Zaorsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu","family":"Nagar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge A.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhardt","family":"Attard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana R.","family":"McKay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth A.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Halabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"Randy","family":"Vince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Ponsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott C.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquibul","family":"Hannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Raben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Mack","family":"Roach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff M.","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard M.","family":"Sandler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Spratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.06.009_b0005","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.clon.2019.04.012","article-title":"Who dies from prostate cancer? An analysis of the Surveillance, Epidemiology and End Results database","volume":"31","author":"Roy","year":"2019","journal-title":"Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0010","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(22)00190-5","article-title":"High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01\/05): 10-year results of a phase 3 randomised, controlled trial","volume":"23","author":"Zapatero","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0015","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1470-2045(21)00705-1","article-title":"Androgen deprivation therapy use and duration with definitive radiotherapy for localised prostate cancer: an individual patient data meta-analysis","volume":"23","author":"Kishan","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0020","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.juro.2017.11.095","article-title":"Clinically localized prostate cancer: AUA\/ASTRO\/SUO guideline. Part I: risk stratification, shared decision making, and care options","volume":"199","author":"Sanda","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0025","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0030","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0035","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2025.06.009_b0040","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1016\/S0140-6736(11)61095-7","article-title":"Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial","volume":"378","author":"Warde","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.06.009_b0045","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.eururo.2016.03.021","volume":"70","author":"Foss\u00e5","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0050","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1056\/NEJM199707313370502","article-title":"Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin","volume":"337","author":"Bolla","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.009_b0055","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(02)09408-4","article-title":"Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial","volume":"360","author":"Bolla","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.06.009_b0060","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.15312","article-title":"Comparison of multimodal therapies and outcomes among patients with high-risk prostate cancer with adverse clinicopathologic features","volume":"4","author":"Kishan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.06.009_b0065","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2018.10.032","article-title":"Comparative effectiveness of radical prostatectomy versus external beam radiation therapy plus brachytherapy in patients with high-risk localized prostate cancer","volume":"75","author":"Berg","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0070","article-title":"Comparative effectiveness of radical prostatectomy and radiotherapy in prostate cancer: observational study of mortality outcomes","volume":"348","author":"Sooriakumaran","year":"2014","journal-title":"BMJ (Online)"},{"key":"10.1016\/j.euo.2025.06.009_b0075","doi-asserted-by":"crossref","first-page":"785.e1","DOI":"10.1016\/j.urolonc.2021.03.017","article-title":"Radical prostatectomy versus external beam radiation therapy for high-grade, clinically localized prostate cancer: emulation of a target clinical trial","volume":"39","author":"Reitblat","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3857\/roj.2021.00486","article-title":"Comparison of radical prostatectomy and external beam radiotherapy in high-risk prostate cancer","volume":"39","author":"Chun","year":"2021","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.euo.2025.06.009_b0085","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1097\/JU.0000000000000805","article-title":"The comparative outcomes of radical prostatectomy versus radiotherapy for nonmetastatic prostate cancer: a longitudinal, population-based analysis","volume":"208","author":"Oake","year":"2022","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2023.09.024","article-title":"Long-term prostate cancer\u2013specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer","volume":"85","author":"Herlemann","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0095","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s10654-013-9873-0","article-title":"When the entire population is the sample: Strengths and limitations in register-based epidemiology","volume":"29","author":"Thygesen","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.euo.2025.06.009_b0100","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.ijrobp.2018.12.011","article-title":"Selection bias in population registry\u2013based comparative effectiveness research","volume":"103","author":"Soni","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.euo.2025.06.009_b0105","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.semradonc.2019.05.011","article-title":"Population-based observational studies in oncology: proceed with caution","volume":"29","author":"Soni","year":"2019","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0110","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1200\/JCO.20.00315","article-title":"Cancer and Leukemia Group B 90203 (Alliance): radical prostatectomy with or without neoadjuvant chemohormonal therapy in localized, high-risk prostate cancer","volume":"38","author":"Eastham","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0115","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1200\/JCO.18.02158","article-title":"Effect of chemotherapy with docetaxel with androgen suppression and radiotherapy for localized high-risk prostate cancer: the randomized phase III NRG Oncology RTOG 0521 trial","volume":"37","author":"Rosenthal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0120","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/jnci\/90.10.766","article-title":"A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer","volume":"90","author":"Kattan","year":"1998","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2025.06.009_b0125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.06.009_b0130","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1002\/sim.8896","article-title":"Estimation and modeling of the restricted mean time lost in the presence of competing risks","volume":"40","author":"Conner","year":"2021","journal-title":"Stat Med"},{"key":"10.1016\/j.euo.2025.06.009_b0135","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0022-5347(05)65971-X","article-title":"Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects","volume":"166","author":"Gleave","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2024.09.009","article-title":"Testosterone recovery following androgen suppression and prostate radiotherapy (TRANSPORT): a pooled analysis of five randomized trials from the Meta-Analysis of Randomized Trials in Cancer of the Prostate (MARCAP) Consortium","volume":"87","author":"Ong","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0145","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0150","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.009_b0155","first-page":"1288","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 1.2023","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2025.06.009_b0160","first-page":"684","article-title":"Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States","volume":"30","author":"Kaye","year":"2024","journal-title":"J Manag Care Spec Pharm"},{"key":"10.1016\/j.euo.2025.06.009_b0165","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1002\/cncr.34905","article-title":"The cost burden of metastatic prostate cancer in the US populations covered by employer-sponsored health insurance","volume":"129","author":"Horn\u00fd","year":"2023","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2025.06.009_b0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12904-024-01410-w","article-title":"Symptoms and quality of life among men starting treatment for metastatic castration-resistant prostate cancer \u2013 a prospective multicenter study","volume":"23","author":"R\u00f6nning\u00e5s","year":"2024","journal-title":"BMC Palliat Care"},{"key":"10.1016\/j.euo.2025.06.009_b0175","first-page":"207","article-title":"Quality of life in prostate cancer patients","volume":"47","author":"Herr","year":"1997","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.euo.2025.06.009_b0180","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1200\/JCO.21.02530","article-title":"Isn\u2019t androgen deprivation enough? Optimal treatment for newly diagnosed metastatic prostate cancer","volume":"40","author":"Morgans","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0185","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1200\/JCO.2022.40.28_suppl.205","article-title":"Health-related quality of life among metastatic prostate cancer survivors: comparisons to survivors originally diagnosed with localized disease and men without a cancer history in the United States","volume":"40","author":"Zheng","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0190","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.009_b0195","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1200\/EDBK_279459","article-title":"Recent advances in the management of high-risk localized prostate cancer: local therapy, systemic therapy, and biomarkers to guide treatment decisions","volume":"40","author":"McKay","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.euo.2025.06.009_b0200","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.clon.2017.10.009","article-title":"Variation in radiotherapy referral and treatment for high-risk pathological features after radical prostatectomy: results from a population-based study","volume":"30","author":"Jin","year":"2018","journal-title":"Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.009_b0205","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1080\/0284186X.2020.1759824","article-title":"Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population-based cohort study","volume":"59","author":"Draulans","year":"2020","journal-title":"Acta Oncol (Madr)"},{"key":"10.1016\/j.euo.2025.06.009_b0210","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.clgc.2020.05.001","article-title":"A nationwide persistent underutilization of adjuvant radiotherapy in North American prostate cancer patients","volume":"18","author":"Rakic","year":"2020","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2025.06.009_b0215","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.euros.2022.04.013","article-title":"Characteristics of patients in SPCG-15\u2014a randomized trial comparing radical prostatectomy with primary radiotherapy plus androgen deprivation therapy in men with locally advanced prostate cancer","volume":"41","author":"Gongora","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.euo.2025.06.009_b0220","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.7765","article-title":"Individual and population comparisons of surgery and radiotherapy outcomes in prostate cancer using Bayesian multistate models","volume":"2","author":"Beesley","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.euo.2025.06.009_b0225","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2214122","article-title":"Fifteen-year outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"388","author":"Hamdy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.009_b0230","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1056\/NEJMoa1606220","article-title":"10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer","volume":"375","author":"Hamdy","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.009_b0235","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2017.02.004","article-title":"Duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG Oncology RTOG 9202","volume":"98","author":"Lawton","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001877?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001877?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:33:06Z","timestamp":1777602786000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001877"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S2588931125001877"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.009","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiotherapy- Versus Surgery-based Treatment Strategy in High-risk Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}